

## Special Issue

# Exosomes in Cancers

### Message from the Guest Editor

Previously considered trash particles, exosomes (30–150 nm extracellular vesicles) play an important role in cancer development and progression. The function of these tiny vesicles depends on their origin. All body cells produce exosomes, and they are present in every bodily fluid. Because exosomes play a crucial role in cancer progression, we would like to invite the submission of manuscripts for this Special Issue entitled “Exomes in Cancer”. We intend to focus on the role of exosomes in cancer progression in this Special Issue. There will be a variety of topics discussed in this Issue, including exosomes activating or inhibiting signaling pathways, immune suppression by exosomes, the role of exosomes in angiogenesis, the role of exosomes in reprogramming the tumor microenvironment, and their role in tumor cell immune escape regulation. In addition, manuscripts that examine the application of exosomes to cancer treatment, either in conjunction with nanoengineered drugs or chemotherapeutics, are welcome.

---

### Guest Editor

Dr. Priyanka Sharma

1. Epigenetic Mechanisms in Cancer Team, Institute of Pharmacology and Structural Biology, 31037 Toulouse, France
2. Montpellier Cancer Research Institute (IRCM), INSERM U1194, 34090 Montpellier, France

---

### Deadline for manuscript submissions

closed (31 January 2024)



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/148430](https://mdpi.com/si/148430)

*Current Issues in Molecular  
Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,  
Christchurch 8140, New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.